Hereditary angioedema (HAE) is a rare genetic disorder that causes unpredictable attacks of swelling in the face, limbs, abdomen, and airway. These attacks can be severe, painful, disabling, and potentially life-threatening.
HAE is estimated to affect less than 8,000 people in the U.S., and less than 15,000 people in Europe.
Most cases of HAE are causes by insufficient levels of functional C1-inhibitor, a protein that regulates plasma kallikrein, a critical mediator of bradykinin-induced edema.
On-demand treatments for HAE can help decrease the severity of an attack as it is occurring, and preventative treatments, taken chronically, can reduce the chance that an attack with occur. However, substantial need remains for effective treatment options with less treatment burden
With navenibart (STAR-0215), our goal is to provide an effective, long-acting preventative treatment for HAE, dosed once every 3 or 6 months, to normalize the lives of people living with HAE by reducing their disease and treatment burden.
